poisar

Stocks · News reference

NeuroOne Medical Technologies shares are trading higher after the company announced it has completed three separate large-animal procedures using its next-generation StereoCED platform.

Aug 27, 2026, 2:03 PMBenzinga Newsdesk
Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

NMTC
Source
benzinga
Observed
Aug 27, 2026, 2:03 PM
Checked
Aug 27, 2026, 2:03 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Aug 27, 2026, 1:08 PMBenzinga Newsdesk

    NeuroOne Completes Three Large-Animal StereoCED Procedures, Including Combined Drug Delivery And Brain Recording; Builds Momentum Toward Planned Launch Of The StereoCED Platform For Human Investigational Clinical Studies Later This Quarter

    Successful Large-Animal Procedures Build Momentum Toward Planned Launch of the StereoCED™ Platform for Human Investigational Clinical Studies Later This Quarter Related StereoCED™ Revenue Expected to be Recognized in

    Read original at benzinga
    NMTC